We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Relationship Between Macular Thickness Measurement and Signal Strength in Optical Coherence Tomography

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01115881
First Posted: May 4, 2010
Last Update Posted: September 27, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Meir Medical Center
  Purpose
Signal strength is a parameter introduced in analysis software version 4.0.1, of the OCT stratus, that combines SNR and uniformity of the signal within a scan The scale of signal strength ranges from 1 to 10, with 1 representing poor image quality and 10 representing excellent image quality It has been showed that signal strength has a better image quality discriminating ability than SNR The operation manual recommends a minimum signal strength of 5 for macular thickness measurement There is no consensus on the level of signal strength above which should be considered to be good quality The inclusion Criteria for acceptable signal strength varies widely in the literature the purpose of our study is to examine the relationship between signal strength and macular thickness measured by stratus OCT

Condition
Optical Tomography

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Relationship Between Macular Thickness Measurement and Signal Strength Using Stratus Optical Coherence Tomography

Further study details as provided by Meir Medical Center:

Enrollment: 40
Study Start Date: May 2010
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
healthy
Criteria

Inclusion Criteria:

  • healthy subjects in this study other than refractive error, all included eyes had no concurrent ocular pathologic features BCVA of at least 20/30, and had spherical refractive error within the range of
  • 4.00 D to 4.00 D

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01115881


Locations
Israel
Meir medical center
Kfar-Saba, Israel
Sponsors and Collaborators
Meir Medical Center
Investigators
Principal Investigator: Ori Segal, M.D Sackler school of medicine Tel-Aviv university
  More Information

Responsible Party: Meir Medical Center
ClinicalTrials.gov Identifier: NCT01115881     History of Changes
Other Study ID Numbers: OCT-1
First Submitted: May 2, 2010
First Posted: May 4, 2010
Last Update Posted: September 27, 2016
Last Verified: January 2010

Keywords provided by Meir Medical Center:
To examine the relationship between signal strength and macular thickness measured by stratus OCT